+44 (0) 20 7549 9987 | USA callers: +1 212 220 8419

Contact Us Now

“Anatomic Pathology Market Report is set to have rapid growth due rising implementation of tissue-diagnostic related procedures in disease screening and favourable reimbursement policies at global, regional and national level, influencing the industry trends in each of the sub-segments from 2019 to 2029”, says Visiongain Report

04 September 2019
Pharma

Visiongain has launched a new pharma report Anatomic Pathology Market Forecast 2019-2029: By Application (Disease Diagnosis, Drug Discovery & Development), By Product & Services (Instruments, Consumables), By End Use, And Segment Forecasts.

The global Anatomic Pathology market is poised for rapid growth between 2019 and 2029. The increase in the incidence of chronic diseases, advances in technology and the increase in the geriatric population are some of the key factors driving market growth.

Advances in technology have witnessed the anatomical pathology market. For example, in November 2018, Greg Clark, business secretary of the UK government, announced that the consortium groups will gather to create five new pathology and digital imaging centers, using artificial intelligence to accelerate the diagnosis of diseases in the United Kingdom, bringing together representatives of various divisions of the sector.

Companies are making continuous efforts to develop advanced and up-to-date pathological equipment with regards to their design and ease of use. Furthermore, there have been several collaborations and agreements between key companies for the introduction of an effective portfolio in order to circumvent the challenges related to disease management.

Leading companies featured in the report include Thermo Fisher Scientific, Inc.; Cardinal Health, Inc.; F. Hoffmann-La Roche AG; Agilent Technologies, Inc.; Sakura Finetek USA, Inc.; Quest Diagnostics Incorporated; Laboratory Corporation of America Holdings; NeoGenomics Laboratories, Inc.; BioGenex; and Bio SB.

Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to sara.peerun@visiongain.com or call her on +44 (0) 207 336 6100.

About Visiongain
Visiongain is one of the fastest growing and most innovative independent media companies in Europe. Based in London, UK, Visiongain produces a host of business-to-business reports focusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.

Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.

Recent News

Visiongain Publishes Drug Delivery Technologies Market Report 2024-2034

The global Drug Delivery Technologies market is estimated at US$1,729.6 billion in 2024 and is projected to grow at a CAGR of 5.5% during the forecast period 2024-2034.

23 April 2024

Read

Visiongain Publishes Cell Therapy Technologies Market Report 2024-2034

The cell therapy technologies market is estimated at US$7,041.3 million in 2024 and is projected to grow at a CAGR of 10.7% during the forecast period 2024-2034.

18 April 2024

Read

Visiongain Publishes Automation in Biopharma Industry Market Report 2024-2034

The global Automation in Biopharma Industry market is estimated at US$1,954.3 million in 2024 and is projected to grow at a CAGR of 7% during the forecast period 2024-2034.

17 April 2024

Read

Visiongain Publishes Anti-obesity Drugs Market Report 2024-2034

The global Anti-obesity Drugs market is estimated at US$11,540.2 million in 2024 and is expected to register a CAGR of 21.2% from 2024 to 2034.

12 April 2024

Read